Evidence-Based Medical News

Mode

All Infectious Disease Oncology Neurology Cardiology Psychiatry Diabetes & Endocrinology Pediatrics Allergy & Immunology Rheumatology Gastroenterology Primary Care & Family Medicine Nutrition & Obesity Medicine Orthopedics & Sports Medicine OB/GYN & Women's Health Radiology & Imaging Genetics & Precision Medicine Pulmonology & Critical Care Anesthesiology & Pain Medicine Physical Medicine & Rehab Nephrology Hematology Urology Ophthalmology Dermatology Emergency Medicine Geriatrics & Aging ENT (Otolaryngology) Palliative Care

Research

Clinical Trials Drug Pipeline Weekly Digests

Reference

Conditions Medications

Community

Text Size

Log in / Sign up

AML

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for AML

16 trials tracked for AML: 2 in phase 3 or 4 and 2 with published results. The most-cited published study has 485 citations.

16Trials tracked

2Phase 3 & 4

0Recruiting

2With published results

Phase distribution

Phase 3 2 Phase 2 11 Phase 1 2 Other / NA 1

Phase 3 (QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive Completed · 485 cited
Phase 3 Controlled Study of Post-transplant Azacitidine for Prevention of Acute Myelogenous Leukemia and Myelodysplastic Syndrome Relapse (VZ-AML-PI-0129) Completed · 215 cited
Phase 2 Standard Idarubicin and Cytarabine for the Treatment of Acute Myeloid Leukemia (AML) Completed
Phase 2 A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML) Completed
Phase 2 Pilot of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor HCT Completed
Phase 2 Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies Completed

Show 10 more trials

Phase 2 A Study Evaluating Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Naïve Participants With Acute Myelogenous Leukemia Completed
Phase 2 Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHD Completed
Phase 2 SGI-110 in Participants With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) Completed
Phase 2 Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006) Completed
Phase 2 Phase I/II Trial of CPX-351 + Palbociclib in Patients With Acute Myeloid Leukemia Completed
Phase 2 Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for Relapsed or Refractory Acute Myeloid Leukemia Completed
Phase 2 Fludarabine and Cytarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) Completed
Phase 1 Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function Completed
Phase 1 A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status Completed
N/A Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML) Completed

Showing the 16 most-cited and recently-updated of 16 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

AML: what the trials found

Clinical evidence for AML includes the use of Azacitidine in various study contexts [2, 15]. Cytarabine has also been evaluated as an intervention in established trials [8, 12].

In a Phase 3 trial comparing Quizartinib to salvage chemotherapy, no statistically significant difference was found in event-free survival (6.0 vs. 3.7; p=0.2034) ¹.

Recent results — preliminary, needs further review

Palcociclib ³
FF-10501-01 ⁴
Guadecitabine (demonstrated LINE-1 demethylation and various response rates in r/r AML and MDS) ⁵
Venetoclax ⁶
Etoposide ⁷

For the clinician treating this condition

Quizartinib did not show a statistically significant improvement in event-free survival compared to salvage chemotherapy in Phase 3 trials ¹.
Azacitidine and Cytarabine are established interventions within the current evidence base [2, 8, 12, 15].

AI synthesis of 6 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.